Premium
Recovery of the response to biological treatments using narrow band ultraviolet‐ B in patients with moderate to severe psoriasis: a retrospective study of 17 patients
Author(s) -
Belinchón Isabel,
Arribas María Paloma,
Soro Pilar,
Betlloch Isabel
Publication year - 2014
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/phpp.12134
Subject(s) - medicine , psoriasis , adalimumab , etanercept , infliximab , ustekinumab , retrospective cohort study , ultraviolet b , ultraviolet therapy , efalizumab , dermatology , puva therapy , plaque psoriasis , tumor necrosis factor alpha
Summary Background/Purpose Biological therapy has demonstrated a very satisfactory anti‐psoriatic effect; however, the loss of response with time has been reported. Objective To evaluate the efficacy of the narrow band ultraviolet‐ B phototherapy ( NB ‐ UVB ) as a rescue in patients with moderate to severe psoriasis who have lost efficacy in their biological treatment. Methods A retrospective chart review study was conducted on patients with moderate to severe psoriasis receiving treatment with a biologic, with a good initial response that subsequently had lost efficacy. All the patients received combined treatment with NB ‐ UVB . Results Seventeen patients were included, with a mean age of 44 years. The biologics were: 8 etanercept, 4 adalimumab, 3 ustekinumab, 1 efalizumab, and 1 infliximab. The mean NB ‐ UVB sessions was 25 (7–48 sessions), with a mean accumulated dose of 31.12 J/cm 2 (5.2–94.6 J/cm 2 ). Sixteen patients had the following results: 44% PASI 90–100, 31.3% PASI 75–89, and 25% PASI 50–74 response. Conclusion According to this study on clinical practice, it could be considered that the use of NB ‐ UVB along with biological drugs that have lost efficacy in controlling moderate to severe psoriasis in adults could contribute to the recovery of the initial response.